- Giovedì, 16 Novembre 2017
- Ultima modifica: Lunedì, 03 Dicembre 2018 11:53
- Visite: 19422
Director Prof. Alessandro Maria Vannucchi
Committee for the coordination of activities
Fabio Almerigogna (Immunoallergology)
Marco Carini (Department of Oncology and Robotics Surgery )
Stefano Colagrande (Radiology)
Giampaolo Corti (Infectious and Tropical Diseases)
Pierangelo Geppetti (Clinical Pharmacology)
Rossella Marcucci (Atherothrombotic Diseases)
Fabio Marra (Internal Medicine and Hepatology)
not yet identify (Prenatal Medicine, Regional Reference Center for Maternal-Fetal Medicine - High-Risk Pregnancy )
Fabio Mori (Cardiovascular diagnostic centre)
Corrado Poggesi (Department of Experimental and Clinical Medicine UNIFI)
Laura Rasero (Research and development of Clinical Practice)
Luisa Margherita Siliani (Surgery Unit)
Helth care director: not yet identify
After a first positive experience with the “Laboratorio congiunto” for the Study of Chronic Mieloproliferative Diseases for clinical and preclinical research, AOUC and the University of Florence have established the CRIMM (Prov. DG178/15) to enhance the capacity to create technological-organizational innovation and
Myeloproliferative neoplasms (MPN), previously called myeloproliferative disorders (MPD), are a group of diseases that affect normal blood cell production in the bone marrow. In this case the bone marrow causes an overproduction of one or more blood cell types (red cells, white cells or platelets).
MMPs include classical entities (such as Polycythemia Vera, Essential Thrombocythemia, Primary and Secondary Mielofibrosis) and rare disorders including Hypereosinophilic Syndromes and Systemic Mastocytosis.
It course is chronic, even if in some cases survival can be rediced in comparison withnormal population, particularly in Mielofibrosis. Moreover, in the last few years a significant improvement in the prognostication of these diseases have been reported, also thanks to an early diagnosis, a better prevention and management of complications, for the availability of new drugs. However, the prevalence of MPNs is increasing.
A growing knowledge in this field requires continuous update of diagnostic technologies and clinical management in order to provide earlier and accurate diagnosis and to promote targeted therapeutic approaches in the spirit of "personalized medicine".
Valentina Ariu (biotecnologist) research laboratory
Manjola Balliu (biotechnologist) research laboratory
Niccolò Bartalucci (biotechnologist) research laboratory
Laura Calabresi (biotechnologist) research laboratory
Giacomo Coltro (medical doctor) PhD fellow
Elisa Contini (biotechnologist) bioinformatician
Giuditta Corbizi Fattori (biotechnologist) diagnostic laboratory
Tiziana Fanelli (biotechnologist) diagnostic laboratory
Annalisa Franci (nurse) research nurse
Francesca Gesullo (biotechnologist) diagnostic laboratory
Paola Gugliemelli (hematologist) clinical activity, diagnostic, molecular and research laboratory
Giuseppe Gaetano Loscocco (medical doctor) PhD fellow
Carmela Mannarelli (biologist) diagnostic and research laboratory
Francesco Mannelli (hematologist) clinical activity
Ilaria Maddalena Marone (biotechnologist) data manager
Annalisa Pacilli (biotechnologist) research laboratory
Chiara Paoli (biotechnologist) study coordinator
Giada Rotunno (biotechnologist) research laboratory
1. To Develop and to transfer innovative clinical care models for MPN patients
2. To Develop and to optimize clinical and diagnostic workup already in place in AOU Careggi
3. To Develop and to make available advanced diagnostic technologies in clinical practice
4. To Contribute to overall advancement of the knowledge in this field by means a clinical and experimental research
5. To Make available the most modern therapeutic options, with the development of Sponsored or Investigator Initiatedclinical trials.
The diagnostic-therapeutic welfare is coordinated by CRIMM doctors in close collaboration with specialists from other AOU Careggi disciplines.
Subjects with a suspect of MPN coming from the territory, from other regional or extra-regional structures, could enter in an Advanced Diagnostic Pathway plan programmed at the first access and than patient will be followed by clinical, therapeutic and monitoring visits.
Clinical Trial Unit (CTU)
1. Develops Investigator’s initiated protocols, within the limits of independent clinical research, and participates in controlled Phase I-IV clinical trials with the use of new drugs; these activities use a strong collaboration with other AOUC structures.
2. Develops standard operating procedures to optimize the carrying out of Phase I-IV clinical trials, in accordance with Good Clinical Practice and Clinical Trials Reference Standards.
3. It has conducted over 40 clinical trials in the last 5 years and it has contributed to approve newly MPN drugs; in particular, CRIMM was the coordinator center in the international RESPONSE registration study.
Active clinical trials with open enrollment
- MPD 106 Research Tissue Bank - observational no profit
- MPD 107 Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative Myeloproliferative Neoplasms (MPN) - observational no profit
- DSC/11/2357/44 Long term study evaluating the effect of Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasm - interventional profit
- CINC424A2X01B An open label, multi-center, Phase IV roll-over protocol for patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study and are judged by the investigator to benefit from continued treatment - interventional profit
- CINC424AIT04 Ruxolitinib Observational study in Myelofibrosis treated patiEnts in Italy - ROMEI - observational profit
- CINC424A2411 A multicenter phase II, open label, single arm study to evaluate the efficacy and safety of ruxolitinib in the treatment of anemic myelofibrosis patients - interventional profit
- INCB 54828-203 A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of incb054828 in Subjects with Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangements - interventional profit
- LOW-PV: The Benefit/Risk Profile of AOP2014, in addition to phlebotomy, in Low-risk Patients With PV – interventional no profit
1. It Performed molecular tests for diagnostic purposes and for monitoring disease and therapy
2. It Is the referent for the JAKNet Italian standardization project
3. It Is a local and national reference for a variety of examinations, the use of advanced technologies and a large number of surveys.
4. It is involved in basic and translational pharmacology research, cellular and molecular biology and advanced molecular diagnostics tools with the aim of achieving rapid transferable results in clinical practice.
Education – ECM credits
For the high level of specialization achieved, the CRIMM is an attractive model for educational activities at national and international level, with the organization of Preceptorships program for clinicians and biologists/biotechnologists.
• MPN SYMPTOMS
• MPN-Score APP
Go to the publications
Every year, CRIMM organizes “La Giornata Fiorentina” dedicated to all people with a diagnosis of MPN and their family, with educational purposes, see www.mpn-florence.com